Analysts are weighing in today on biotech company Biogen Idec Inc. (NASDAQ:BIIB - 148.15), biopharmaceutical issue Celgene Corporation (NASDAQ:CELG - 77.12), and restaurant operator Yum! Brands, Inc. (NYSE:YUM - 72.39). Here's a quick roundup of today's bullish brokerage notes.

• Brean Capital initiated coverage of BIIB with a "buy" recommendation this morning, which could add to the stock's year-to-date gain of roughly 35%. However, bearish traders seem unfazed by the equity's technical strength. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows a 10-day put/call volume ratio of 1.10 for BIIB, confirming puts bought to open have outnumbered calls during the past two weeks. This ratio arrives in the 81st annual percentile, reflecting a stronger-than-usual preference for puts over calls.
  
  
• CELG -- which has climbed about 25% during the past year -- was also started with a "buy" endorsement at Brean Capital today. Meanwhile, near-term options players appear to be bullishly biased toward the stock lately. The equity's Schaeffer's put/call open interest ratio (SOIR) checks in at 0.58, indicating calls nearly double puts among options scheduled to expire in the next three months. This ratio is docked in the 14th percentile of its annual range, meaning short-term traders have rarely been more call-heavy toward CELG during the past year.
  
  
• Up nearly 33% from the year-ago period, YUM was initiated with an "outperform" rating and a price target of $93 at Macquarie ahead of the opening bell. The security has also bested the broader S&P 500 Index (SPX) by nearly 15 percentage points during the past three months. Not surprisingly, most of the analysts covering YUM maintain high expectations for the stock. The restaurateur boasts 12 "strong buys" and two "buy" recommendations, compared to six "holds" and not a single "sell" suggestion.